PharmaEngine, Inc. (TPEX:4162)

Market Cap	8.25B -14.8%
Revenue (ttm)	1.03B -58.7%
Net Income	538.80M -67.0%
EPS	3.75 -66.9%
Shares Out	143.68M
PE Ratio	15.31
Forward PE	n/a
Dividend	2.00 (3.48%)
Ex-Dividend Date	Aug 17, 2026

Volume	168,496
Open	56.80
Previous Close	56.60
Day's Range	56.80 - 57.60
52-Week Range	53.00 - 74.40
Beta	0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 45
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error